Testosterone is a steroidal compound characterised by the tetracyclic gonane skeleton, with structural modifications at key ring positions determining receptor selectivity and relative binding affinity at glucocorticoid, androgen, oestrogen, mineralocorticoid, or progesterone receptors. Ligand binding stabilises a receptor conformation that recruits co-activator complexes and translocates to the nucleus, modulating hormone-responsive gene transcription. The very low nanomolar concentrations at which Testosterone produces measurable receptor-mediated effects in target tissues define the basis for pharmacologically-based OEL derivation rather than conventional NOAEL-based approaches.
PDE derivation for Testosterone applies the composite uncertainty factor methodology: F1 accounts for interspecies pharmacokinetic and pharmacodynamic differences (default 12 for rat-to-human, refinable with toxicokinetic AUC bridging data), F2 covers intraspecies variability in the human population including sensitive subgroups (default 10), F3 ad
